The aim of the new variations framework is to streamline post-approval change handling, particularly the assessment and processing of variations.
Marketing Authorization Holders (MAHs) for medicinal products authorised in the EU via the Centralised Procedure or National Procedures such as the Decentralised and Mutual-Recognition Procedure should be aware of the updated legislation and guidance.
If you are looking for comprehensive Regulatory Intelligence support that monitors changes to key legislation and guidance, please don’t hesitate to get in touch with one of our experts today!